University of Rochester Medical Center

Over the last five years, the URMC has garnered more than $1.18 billion in biomedical research funding, common and rare illnesses, landing the University in the top 26th percentile of U.S. medical centers in Federal research funding. Coupled with one million square feet of state-of-the-art research space, and high-end support services and shared resources, we’re building upon this strong legacy of research every day. Our scientists contributed vaccine technology: HPV vaccine, protecting against cervical cancer, newborns worldwide receive a vaccine that URMC researchers created against Haemophilus influenza type B (Hib), virtually wiping out a leading cause of meningitis in preschoolers. And we conducted the first pivotal, H5N1 bird flu efficacious and safety study, and ready to administer if faced with a pandemic. The Medical Center also has a long history in HIV research, being one of the first sites in the United States to conduct HIV vaccine studies. The NIH-sponsored University of Rochester HIV/AIDS Clinical Trials Unit, or The Rochester Victory Alliance, participated in more than 275 HIV treatment and vaccine trials, enrolling upwards of 3,500 volunteers since 1987.